Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln
I'm PortAI, I can summarize articles.
Palatin's fiscal Q1 2026 revenue reached $8.8 million, driven by a collaboration with Boehringer Ingelheim. The company reported a net income of $4.7 million, reversing last year's loss. Palatin completed an $18.2 million public offering, regaining NYSE American compliance. Future plans include IND submission and Phase 1 trial for PL7737, and mid-2026 IND filing for MC4R agonists. The FDA granted Orphan Drug Designation for leptin receptor deficiency obesity.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments